NO20025755D0 - Formulering basert på heparin, glykosaminoglykan eller heparinoid, bruk avformuleringen eller formuleringsbasen - Google Patents

Formulering basert på heparin, glykosaminoglykan eller heparinoid, bruk avformuleringen eller formuleringsbasen

Info

Publication number
NO20025755D0
NO20025755D0 NO20025755A NO20025755A NO20025755D0 NO 20025755 D0 NO20025755 D0 NO 20025755D0 NO 20025755 A NO20025755 A NO 20025755A NO 20025755 A NO20025755 A NO 20025755A NO 20025755 D0 NO20025755 D0 NO 20025755D0
Authority
NO
Norway
Prior art keywords
formulation
heparinoid
glycosaminoglycan
heparin
formulations
Prior art date
Application number
NO20025755A
Other languages
English (en)
Norwegian (no)
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of NO20025755D0 publication Critical patent/NO20025755D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Materials For Medical Uses (AREA)
NO20025755A 2000-05-30 2002-11-29 Formulering basert på heparin, glykosaminoglykan eller heparinoid, bruk avformuleringen eller formuleringsbasen NO20025755D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10026699A DE10026699A1 (de) 2000-05-30 2000-05-30 Formulierung auf Heparin-, Glycosaminoglycan- oder Heparinoidbasis und Verwendung der Formulierung sowie der Formulierungsgrundlage
PCT/EP2001/006115 WO2001091729A1 (de) 2000-05-30 2001-05-29 Formulierung auf heparin-, glycosaminoglykan- oder heparinoidbasis und verwendung der formulierung sowie der formulierungsgrundlage

Publications (1)

Publication Number Publication Date
NO20025755D0 true NO20025755D0 (no) 2002-11-29

Family

ID=7644040

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20025755A NO20025755D0 (no) 2000-05-30 2002-11-29 Formulering basert på heparin, glykosaminoglykan eller heparinoid, bruk avformuleringen eller formuleringsbasen
NO20025759A NO20025759L (no) 2000-05-30 2002-11-29 Formulering basert på heparin, glykosaminoglykan eller heparinoid, anvendelse av formuleringen og formuleringsbasen

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20025759A NO20025759L (no) 2000-05-30 2002-11-29 Formulering basert på heparin, glykosaminoglykan eller heparinoid, anvendelse av formuleringen og formuleringsbasen

Country Status (13)

Country Link
US (1) US7393840B2 (enExample)
EP (1) EP1284717B1 (enExample)
JP (1) JP5198708B2 (enExample)
CN (1) CN100391440C (enExample)
AT (1) ATE349202T1 (enExample)
AU (1) AU2001266033A1 (enExample)
BR (1) BR0111257A (enExample)
CA (1) CA2409828C (enExample)
DE (2) DE10026699A1 (enExample)
ES (1) ES2278750T3 (enExample)
NO (2) NO20025755D0 (enExample)
RU (1) RU2278658C2 (enExample)
WO (1) WO2001091729A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2359945C (en) * 1999-11-12 2011-04-26 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
DE10026698A1 (de) * 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
DE50105650D1 (de) * 2000-12-16 2005-04-21 Aventis Pharma Gmbh Verwendung von niedermolekularen heparin zur behandlung von osteoarthrose
GB0205868D0 (en) * 2002-03-13 2002-04-24 Univ Nottingham Polymer composite with internally distributed deposition matter
JP4416664B2 (ja) * 2002-05-03 2010-02-17 マサチューセッツ・インスティテュート・オブ・テクノロジー Δ４，５グリクロニダーゼおよびその使用
SE0201922D0 (sv) * 2002-06-20 2002-06-20 Ltp Lipid Technologies Provide Koagulationshindrande komposition (Anticoagulant Composition)
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
WO2005042623A1 (en) * 2003-10-23 2005-05-12 University Of Nottingham Preparing active polymer extrudates
EP1711595B1 (en) * 2003-12-02 2007-11-21 Universiteit Gent Use of polysulphated alginate in cellular matrices
EP1537871A1 (en) * 2003-12-04 2005-06-08 Aventis Pharma S.A. Enoxaparin for the treatment of cancer
US7563780B1 (en) * 2004-06-18 2009-07-21 Advanced Cardiovascular Systems, Inc. Heparin prodrugs and drug delivery stents formed therefrom
JP5258144B2 (ja) * 2004-12-21 2013-08-07 株式会社分子生理化学研究所 吸収性の改善された固形状のコエンザイムｑ１０経口製剤の製造方法
US7691830B2 (en) * 2005-02-17 2010-04-06 Clive Elson Method and composition for treatment of a mucosal tissue disorder
MY148074A (en) * 2005-05-10 2013-02-28 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant
US8802156B2 (en) 2007-11-14 2014-08-12 Laboratorios Farmacéuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
GB0812742D0 (en) * 2008-07-11 2008-08-20 Critical Pharmaceuticals Ltd Process
US20110305658A1 (en) * 2008-12-11 2011-12-15 L'oreal S.A. Lengthening mascara composition
WO2010113176A2 (en) * 2009-03-31 2010-10-07 Reliance Life Sciences Pvt. Ltd. Novel copolymers for controlled release delivery system
ES2363964B1 (es) 2009-11-20 2012-08-22 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados.
WO2011088418A2 (en) * 2010-01-15 2011-07-21 Mount Sinai School Of Medicine Inhibition of tnf-alpha induced activation of nfkb by pentosan polysulfate
WO2014142938A1 (en) * 2013-03-15 2014-09-18 Aihol Corporation Pharmaceutical formulation containing glycosaminoglycan
US10897918B1 (en) * 2013-03-15 2021-01-26 Mccormick & Company, Incorporated Extrusion encapsulation with narrow particle size and shape distribution, high solubility, and low surface oil
US9539265B2 (en) 2013-03-15 2017-01-10 Aihol Corporation Pharmaceutical formulation containing glycosaminoglycan
JP6877996B2 (ja) * 2016-12-27 2021-05-26 小林製薬株式会社 外用組成物
JP6877997B2 (ja) * 2016-12-27 2021-05-26 小林製薬株式会社 外用組成物
WO2019236453A1 (en) * 2018-06-03 2019-12-12 Glycomira Therapeutics, Inc. Methods for preventing a serious health consequence and/or tissue damage after exposure to ionizing radiation and /or chemotherapy
US20210069237A1 (en) * 2019-09-09 2021-03-11 Harrow Ip, Llc Pharmaceutical compositions comprising heparinoids and methods for preparing thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1107041A (en) * 1913-10-25 1914-08-11 Benjamin H Cook Coupling device.
JPS58101311A (ja) * 1981-12-11 1983-06-16 Toshiba Corp 多相電圧電流変換回路
DE3331009A1 (de) * 1983-08-27 1985-03-14 Basf Ag, 6700 Ludwigshafen Verfahren zur erhoehung der enteralen resorbierbarkeit von heparin bzw. heparinoiden sowie das so erhaeltliche heparin- bzw. heparinoidpraeparat
JPS6054313A (ja) * 1983-09-01 1985-03-28 Terumo Corp 腸管吸収性ヘパリン組成物
US4925673A (en) 1986-08-18 1990-05-15 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
SE9200951D0 (sv) * 1992-03-27 1992-03-27 Kabi Pharmacia Ab Pharmaceutical composition containing a defined lipid system
US5346701A (en) * 1993-02-22 1994-09-13 Theratech, Inc. Transmucosal delivery of macromolecular drugs
SE9302135D0 (sv) * 1993-06-18 1993-06-18 Kabi Pharmacia Ab New pharmaceutical composition
AU692506B2 (en) * 1993-11-17 1998-06-11 Ibah, Inc. Transparent liquid for encapsulated drug delivery
US6333021B1 (en) * 1994-11-22 2001-12-25 Bracco Research S.A. Microcapsules, method of making and their use
DE19531277A1 (de) * 1995-08-25 1997-02-27 Basf Ag Verwendung von Lipiden als Hilfsmittel bei der Herstellung von festen Arzneiformen nach dem Schmelzextrusionsverfahren
FR2775188B1 (fr) 1998-02-23 2001-03-09 Lipha Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
DE69917609T2 (de) * 1998-03-05 2005-06-09 Phares Pharmaceutical Research N.V., Curaçao Arzneimittel und deren verwendung
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents

Also Published As

Publication number Publication date
EP1284717A1 (de) 2003-02-26
AU2001266033A1 (en) 2001-12-11
JP2003534370A (ja) 2003-11-18
CN1450891A (zh) 2003-10-22
WO2001091729A1 (de) 2001-12-06
ATE349202T1 (de) 2007-01-15
US7393840B2 (en) 2008-07-01
DE50111738D1 (de) 2007-02-08
CN100391440C (zh) 2008-06-04
NO20025759D0 (no) 2002-11-29
CA2409828C (en) 2010-08-03
RU2278658C2 (ru) 2006-06-27
NO20025759L (no) 2003-01-14
ES2278750T3 (es) 2007-08-16
DE10026699A1 (de) 2001-12-06
BR0111257A (pt) 2003-06-10
JP5198708B2 (ja) 2013-05-15
US20030161884A1 (en) 2003-08-28
EP1284717B1 (de) 2006-12-27
CA2409828A1 (en) 2001-12-06

Similar Documents

Publication Publication Date Title
NO20025755D0 (no) Formulering basert på heparin, glykosaminoglykan eller heparinoid, bruk avformuleringen eller formuleringsbasen
BRPI0410956A (pt) pelìculas com base em óxido de polietileno e sistemas de liberação de droga feitos delas
ATE288256T1 (de) Dermale zusammensetzungen
BR0113663A (pt) Composições de pelìcula de pectina
BR0106238B1 (pt) massa para moldagem com boa capacidade de moldagem por sopro, bem como uso da referida massa de moldagem e artigo moldado que a contÉm.
ATE536869T1 (de) Auf glucan-film basierte wirkstoffverabreichungssysteme
BRPI0416613A (pt) composição e forma de dosagem compreendendo uma molécula anfifìlica como um veìculo de suspensão
ATE382655T1 (de) Polymerzusammensetzungen aus polymeren und ionischen flussigkeiten
DE60231862D1 (de) Erodierbare polymere zur injektion
AU2001279631A1 (en) Self-emulsifying active substance formulation and use of this formulation
BRPI0411678A (pt) nanopartìculas de ácido hialurÈnico
DE60326859D1 (de) Arzneimittelverabreichung
BRPI0407882A (pt) conjugados de polìmero-porção de fator viii
BR0212389A (pt) Produção de materiais biopolìmeros como pelìcula, fibra, espuma ou adesivo a partir de derivados solúveis de queratina s-sulfonada
KR910007508A (ko) 서방출 드레싱용 제제 및 이의 용도
DE60030542D1 (de) Nicht stechendes überzugsmittel
ES2570856T3 (es) Composiciones oftálmicas que contienen una combinación sinérgica de dos polímeros
BR0307893A (pt) Formulação oftálmica com sistema de goma
MXPA05003591A (es) Materiales basados en ciclodextrina, composiciones y usos relacionados a los mismos.
KR930016091A (ko) 거의 수불용성인 약제의 고체 분산액을 제조하는 방법
WO2004112713A3 (en) Drug polymer complexes
BR9901782A (pt) Forma para dosagem de nefazodona.
ATE228828T1 (de) Verfahren zur herstellung von festen cyclodextrinhaltigen dosierungsformen
BR9809483A (pt) Composição de reticulação, processo para faze-la, e, uso da mesma.
BR0313428A (pt) Composições farmacêuticas de drogas semi-ordenados e polìmeros